Form 4: Amneal Pharmaceuticals Co-CEO Chintu Patel Reports Stock Unit Grants in Form 4 Filing

Co-CEO of Amneal Pharmaceuticals, Chintu Patel, reports the acquisition of restricted stock units and performance-based restricted stock units in a recent SEC Form 4 filing.

Summary

• Chintu Patel, Co-CEO of Amneal Pharmaceuticals, filed a Form 4 with the SEC on March 5, 2024.
• The filing reports the acquisition of 370,370 restricted stock units and 1,333,334 performance-based restricted stock units on March 4, 2024.
• The restricted stock units vest in four equal annual installments beginning on March 4, 2025.
• The performance-based restricted stock units vest based on Amneal's Class A Common Stock achieving certain average closing price targets at the end of a three-year performance period, with vesting occurring on February 28, 2027.
• The number of shares received upon vesting of the performance-based restricted stock units may vary from 0% to 200% of the target number.
• Patel has granted Denis Butkovic and Chris Daly power of attorney to execute and deliver forms related to his ownership of Amneal Pharmaceuticals securities.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The sentiment is moderately positive as it reflects executive compensation aligned with company performance.

Positives

• The grant of restricted stock units and performance-based restricted stock units aligns the Co-CEO's interests with those of the shareholders.
• The vesting schedule for the restricted stock units encourages long-term commitment.
• The performance-based vesting criteria for the performance-based restricted stock units incentivize the achievement of specific stock price targets.

Risks

• The value of the restricted stock units and performance-based restricted stock units is dependent on the performance of Amneal Pharmaceuticals' stock.
• The performance-based restricted stock units may not vest if the stock price targets are not met.
• The vesting of a large number of shares could potentially dilute existing shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the performance-based restricted stock units is tied to the future performance of Amneal Pharmaceuticals' stock price.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry. Equity grants are often used to incentivize management and align their interests with shareholders.

Comparison to Industry Standards

• Equity compensation packages for CEOs in the pharmaceutical industry typically include a mix of stock options, restricted stock units, and performance-based awards.
• The vesting schedules and performance metrics used in Amneal Pharmaceuticals' equity grants are likely comparable to those used by other companies in the industry, such as Teva Pharmaceuticals, Mylan (now Viatris), and Sun Pharmaceutical Industries.
• The specific terms of the grants, such as the number of shares and the performance targets, would need to be compared to industry benchmarks to assess their competitiveness.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the potential for increased stock value.
• The grants have no immediate impact on customers, suppliers, or creditors.

Next Steps

• The restricted stock units will vest according to the specified schedule.
• The performance-based restricted stock units will vest based on the achievement of stock price targets.
• Further SEC filings may be required to report any subsequent transactions in Amneal Pharmaceuticals' securities by Chintu Patel.

Key Dates